ClinicalTrials.gg
RecruitingNCT07264088FOLLOW-UPUpdated Nov 19, 2026

Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer

An observational study in Prostate Cancer, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Imperial College London · Observational

How we know

Updated Nov 19, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100,000
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Prostatic Neoplasms by Imperial College London — 4 open to participants now, 6 under way, none of them phase 3. Prostatic Neoplasms · Imperial College London.

Started
2026
the only one that year
Observational
6 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Prostatic Neoplasms by Imperial College London, this one is the only one that started in 2026, is one of 6 observational ones, and was the 13th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 13 studies in Prostatic Neoplasms by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Prostatic Neoplasms by Imperial College London, or all of them as a file.
02

Study summary

Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly. The organisation of these check-ups varies across the country as it is not known which approach is best. The four different established approaches are (i) check-ups performed in hospital outpatients by the same team that provided treatment; (ii) patients seen regularly by their GP with hospital referral as necessary; (iii) planned shared care between general practice and hospital follow up; or (iv) patients supported to provide checks on themselves (self-care) and reaching out to a doctor or a nurse when required. This study will compare these options to establish which is best for patients and makes the best use of the NHS resources.

Read the detailed description

This is a pragmatic, prospective, propensity-matched, cohort study using routine data, with an embedded patient survey, economic evaluation, and qualitative and preference studies. Individual sites will be classified according to one of the four follow up strategies to compare outcomes in a natural experiment. Individual participants will be clustered within their treating hospital.

The main cohort for the study will be identified from the National Disease Registration Service Cancer Registry. Data on treatments, diagnoses, clinic attendances and other events that occur in secondary care from 3 years prior to diagnosis will be extracted from databases linked to the Cancer Registry including Cancer Pathway, Radiotherapy Dataset (RTDS), Systemic Anti-Cancer dataset (SACT) and Hospital Episode Statistics (HES). These datasets are referred to collectively as 'HES-linked data'. HES-linked data will be collected from 3 years prior to diagnosis, to enable analyses to be adjusted for patient medical history and pattern of health service use prior to diagnosis with prostate cancer, to the latest available date (expected to be 31 December 2026).

To identify the most clinically and cost-effective follow up strategy for patients, five interrelated work packages (WPs) will address specific objectives:

- WP1: Determine safety and clinical effectiveness of different follow up strategies

Stage 1: The utility of HES-linked data to study treatment for prostate cancer recurrence will be validated. It will be confirmed if databases contain the parameters required and are complete enough to robustly assess outcomes in secondary care including time to treatment for cancer recurrence and treatment for side-effects from primary treatment. Detailed statistical methods and computer code will be developed for determining whether follow up strategies are equivalent for treatment of recurrence, including methods for dealing with missing patients and treatment variables. A preliminary investigation of hospital adherence to stated follow up strategies will be conducted.

Stage 2: All primary and secondary outcomes will be measured using both HES-linked datasets and information collected through the patient survey in WP2. The methods developed in stage 1 will be used to assess the equivalence of the four follow up strategies for the primary outcome of treatment for cancer recurrence at 3 years, the key secondary outcome of time to hospital treatment for cancer recurrence, and remaining secondary outcomes.

-WP2: Measure side effects of prostate cancer treatments, patient quality of life and recurrence outcomes not captured in routine data

A survey will be designed and administered to capture data from a subgroup of study participants on adverse effects of initial cancer treatment, how those adverse effects were managed, health service utilisation and HRQoL. The survey will ask patients whether and when they received hormone therapy for prostate cancer recurrence, providing data for WP1 on recurrence treatments not captured in HES-linked databases.

-WP3: Identify key patient perspectives on the important features of follow-up

A qualitative interview study will be conducted with patients with lived experience of prostate cancer and follow up, purposively sampling geographic spread, socioeconomic class and ethnicity (WP3 is sponsored by University of Aberdeen and is described in a separate protocol and has separate ethics approvals). Early findings will inform the design of the Discrete Choice Experiment (DCE) to be deployed in WP5.

-WP4: Evaluate the cost-effectiveness of each follow up strategy

The use of primary and secondary health care services during follow up to estimate the costs of the four follow up strategies will be assessed using HES-linked and patient survey data. An economic evaluation model will be developed to compare the patient lifetime costs and outcomes of the four strategies, and identify the approach that provides the best value for money for the NHS.

-WP5: Define patient preferences for follow-up

A DCE will be conducted to understand how patients might respond to follow up strategies with different attributes and elicit patient preferences. Questions for the DCE will be designed using early qualitative findings (WP3) and will be included as a module in the patient survey (WP2) for a subgroup of survey recipients.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • prostate cancer after curative treatment
  • prostate cancer follow up
  • propensity-matched cohort study
  • qualitative
  • discrete choice experiment
  • economic evaluation
  • routine data
  • patient survey
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men aged 18 and over who were newly diagnosed with prostate cancer between January 2018 and December 2023 and completed curative treatment to cure their prostate cancer at a hospital in England between January 2019 and December 2023.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All hospitals in England that provide radical prostatectomy or radical radiotherapy or focal therapy for prostate cancer and are identified by clinicians as receiving one of the four follow up strategies of interest will be eligible for inclusion in the study.

Individual patients satisfying the following criteria will be eligible for inclusion:

  • Having newly-diagnosed non-, clinically localised prostate cancer (ICD-10 code C61) in the Cancer Registry between 1 January 2018 and 31 December 2023;
  • Age 18 or over at diagnosis;
  • Completed primary curative treatment at an eligible hospital between 1 January 2019 and 31 December 2023 with either: radical radiotherapy +/- hormones, or radical prostatectomy with curative intent +/- lymphadenectomy, or focal therapy, in keeping with local practice;
  • Alive with no disease progression or metastasis 6 months after the date of completion of primary curative treatment.

Exclusion criteria

Exclusion criteria:

  • Men who are treated for cancer; or receiving palliative prostate cancer care;
  • Men who have opted out of their data being used as part of national routine data sets will be excluded (https://digital.nhs.uk/services/national-data-opt-out).

Recruitment to the survey component of the study will be limited to a sub-cohort of eligible participants that additionally meet the following criteria:

  • Alive;
  • Have achieved between three to four and a half years of follow up (from completion of initial curative treatment) during the survey period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hospital based follow up

    Exclusively hospital led follow up, face-to-face or remotely by the specialist treating team.

    Other: Hospital based follow up

  • Primary care based follow up

    After the initial hospital follow up, patients are discharged and exclusively managed by (non-specialist) general practices (GP or nurse led) in face-to-face or remote appointments, with hospital referral as necessary.

    Other: Primary care based follow up

  • Planned shared care follow up

    An ongoing combination of general practice and hospital management

    Other: Planned shared care follow up

  • Self-management

    After initial hospital follow up, patients are discharged and managed remotely, with no scheduled review. A tracking system monitors prostate-specific antigen (PSA) tests performed in primary care or secondary care. Patients access support workers for remote consultation to discuss symptoms and request further specialist management as required.

    Other: Self-management

Interventions

  • OtherHospital based follow up

    Exclusively hospital led follow up, face-to-face or remotely by the specialist treating team.

  • OtherPrimary care based follow up

    After the initial hospital follow up, patients are discharged and exclusively managed by (non-specialist) general practices (GP or nurse led) in face-to-face or remote appointments, with hospital referral as necessary.

  • OtherPlanned shared care follow up

    An ongoing combination of general practice and hospital management

  • OtherSelf-management

    After initial hospital follow up, patients are discharged and managed remotely, with no scheduled review. A tracking system monitors prostate-specific antigen (PSA) tests performed in primary care or secondary care. Patients access support workers for remote consultation to discuss symptoms and request further specialist management as required.

06

What researchers measure

Primary outcomes

  1. Safety and clinical effectiveness defined by treatment for cancer recurrence

    Probability of cancer recurrence treatment calculated from analysis of time to recurrence treatment, measured using Hospital Episode Statistics (HES)-linked cancer databases and patient survey that includes domains on cancer recurrence and treatment.

    Time frame: At 3 years following end of initial radical surgery or radiotherapy or focal therapy

  2. Estimate cost-effectiveness

    Modelled cost-effectiveness reported as incremental cost per quality adjusted life year (QALY) gained at different points over patient lifetime from an NHS and personal social services perspective, measured using HES-linked databases and patient survey

    Time frame: At 3 years, extrapolated over the remaining patient lifetime

Secondary outcomes

  1. Time to treatment for cancer recurrence provided in secondary care

    Restricted mean time to treatment for cancer recurrence provided in secondary care, measured using HES-linked databases.

    Time frame: Up to 7 complete years following end of initial radical surgery or radiotherapy or focal therapy

  2. Metastases, cancer specific and overall survival

    Time to metastasis, time to prostate cancer specific death, and overall survival (including time to and cause of non-prostate cancer deaths), measured using HES-linked databases

    Time frame: Up to 7 complete years following end of initial radical surgery or radiotherapy or focal therapy

  3. Cancer recurrence treatments (salvage to cure vs palliative suggesting delayed diagnosis)

    A binary outcome (cancer recurrence treatment) that takes the value 1 if the recurrence treatment was salvage with intent to cure and 0 if the recurrence treatment was palliative. This will be assessed using the type of first treatment received for recurrence, as recorded in HES-linked databases or reported in the patient survey.

    Time frame: Up to 3 years following end of initial radical surgery or radiotherapy or focal therapy

  4. Health related quality of life (HRQoL)

    The EuroQol 5-Dimension 5-Level (EQ-5D-5L) instrument will be used to measure HRQoL in the patient survey. The EQ-5D-5L index values range from a minimum of -0.594 (representing health states considered worse than death) to a maximum of 1.000 (representing full health). In this scoring system, higher values indicate better health-related quality of life outcomes.

    Time frame: At 3 to 4.5 years following end of initial radical surgery or radiotherapy or focal therapy

  5. Health related quality of life (HRQoL)

    The Expanded Prostate Cancer Index Composite 26-item short form (EPIC-26) is collected in the patient survey and measures prostate cancer-specific HRQoL across four domains: urinary, bowel, sexual and hormonal function. Scores for each domain are transformed to a 0-100 scale, where higher values indicate better HRQoL (reflecting less symptom burden and greater functional well-being).

    Time frame: At 3 to 4.5 years following end of initial radical surgery or radiotherapy or focal therapy

  6. Physical and psychological complications of treatment

    Including those resulting in specialist referrals or prescribing, measured using HES-linked databases and patient survey

    Time frame: At 3 years following end of initial radical surgery or radiotherapy or focal therapy

  7. Prostate cancer core outcome set (COS)

    COS measures relevant to follow up and treatment not otherwise captured: perioperative deaths, positive surgical margin, thromboembolic disease, urethral stricture and side-effects of hormonal therapy, measured using patient survey and HES-linked databases.

    Time frame: At 3 years following end of initial radical surgery or radiotherapy or focal therapy

  8. Patient experience and satisfaction

    Measured from the Discrete Choice Experiment (DCE). DCE reported as % uptake of follow-up with minimum score 0% and maximum score 100%.

    Time frame: For the qualitative study: At enrolment for the qualitative study. For the DCE: At 3 to 4.5 years following end of initial radical surgery or radiotherapy or focal therapy

  9. Adherence to follow up strategy

    Level of adherence to each follow up strategy is based on outpatient clinic attendance recorded in HES-linked databases and GP attendance reported in the patient survey. Measurement will involve counts of appointments from both sources combined and compared with the expected count based on the follow up strategy in use at each participating centre. For each treatment type (surgery, radiotherapy and focal therapy) a measure of adherence will be derived and reported. Full details will be developed and reported in the Statistical Analysis Plan before data analysis.

    Time frame: At 3 years following end of initial radical surgery or radiotherapy or focal therapy

  10. Costs to health services

    Total cost of health services used in primary and secondary care, measured using HES-linked databases and patient survey.

    Time frame: Measured at up to 7 years as well as at 3 years (for consistency with the key primary and secondary outcomes estimated in work package 1), following end of initial radical surgery or radiotherapy or focal therapy.

07

Study locations

1 of 1 sites recruiting
  • London School of Hygiene & Tropical Medicine
    London, WC1E 7HT, United Kingdom
    Recruiting
    • Diana Johnson · Contactfollowup@abdn.ac.uk · +44 (0) 1224438144
    • Linda Sharples · Principal investigator
    • Luke Vale · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — In development

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 7 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Dec 4, 2025
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
London School of Hygiene & Tropical Medicine is now Recruiting
Nov 19, 2026
Start date
Oct 2026→Dec 2026
Oct 6, 2026
Show all 2 updates
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    London School of Hygiene & Tropical Medicine is now Recruiting
    + 1 other change: verification date
  2. Oct 6, 2026
    Start date Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07264088
Collaborators
London School of Hygiene and Tropical Medicine, University of Aberdeen, University of Leeds, Cardiff University, University of Sheffield, University of Southampton, University College, London, Royal Marsden NHS Foundation Trust, North Bristol NHS Trust, Cardiff and Vale University Health Board, Liverpool University Hospitals NHS Foundation Trust, National Institute for Health Research, United Kingdom
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Diana Johnson, BSc (Hon)
Contact
followup@abdn.ac.uk
+44 (0) 1224 438144
Rakesh Heer, BMed Sci MB BS MRCS PhD FRCS
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion